Testosterone Cypionate and Prednisone Interaction: What Clinicians and Patients Need to Know

Print or save as PDFOpens the printable medication review sheet and your print dialog. No sign-up.

The direct answer

Testosterone cypionate and prednisone are not contraindicated together. Testosterone labeling lists corticosteroids and ACTH as a combination that may increase fluid retention and advises caution, especially in people with heart, kidney or liver disease. The Depo-Testosterone contraindication list names hypersensitivity, breast cancer, known or suspected prostate cancer, pregnancy and serious cardiac, hepatic or renal disease; prednisone is not on it [1].

That does not make the pair risk-free. Prednisone has its own dose- and duration-dependent effects on glucose, bone and infection risk [2][3][4][5][6], and testosterone has labeled effects on blood pressure and red cell mass [1][7]. Beyond the fluid-retention warning, these effects are described separately, and no study measured the net effect of the two drugs together.

What each drug is

Testosterone cypionate is an injectable testosterone ester labeled for men with hypogonadism caused by testicular failure or by pituitary or hypothalamic disease [1]. It is a Schedule III controlled substance [1]. Prednisone is an oral glucocorticoid used for inflammatory and immune conditions, at doses that vary widely by condition.

Fluid retention and blood pressure: the overlap

Fluid retention is the most specific interaction named for this pair. The Depo-Testosterone label lists edema, with or without congestive heart failure, as a possible serious complication in patients with pre-existing cardiac, renal or hepatic disease, and lists retention of sodium, chloride, water, potassium, calcium and inorganic phosphates as an adverse reaction of androgens [1]. Prednisone labeling also lists salt and water retention and high blood pressure among its effects.

Testosterone also raises blood pressure. The Depo-Testosterone label says testosterone can increase blood pressure, which can increase cardiovascular risk over time, and that testosterone products are not recommended in uncontrolled hypertension [1]. FDA's 2025 class-wide labeling action says ambulatory blood pressure studies confirmed a blood pressure increase with all testosterone products [9]. A person on both drugs who develops edema or a rising blood pressure has two possible contributors, and the label does not provide a way to separate them.

Blood glucose: opposite directions

Prednisone can raise blood glucose. In a review of 50 hospitalized patients on high-dose corticosteroids (40 mg/day prednisone or more for at least 2 days), 32 (64%) had at least one glucose of 200 mg/dL or higher; among 34 patients without a history of diabetes, 19 (56%) had hyperglycemia at least once [5]. This was a small single-center study, so it does not give a rate for a routine outpatient course.

The Depo-Testosterone label points in the other direction: in diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements [1].

Bone: prednisone risk

Prednisone's bone effect is dose- and duration-dependent. In a UK cohort of 244,235 oral corticosteroid users and matched controls, the relative rate was 2.60 for vertebral fracture and 1.61 for hip fracture; vertebral fracture risk rose from 1.55 at under 2.5 mg/day prednisolone to 5.18 at 7.5 mg/day or more [3]. The 2022 American College of Rheumatology guideline strongly recommends fracture-risk assessment for adults beginning or continuing more than 3 months of glucocorticoids at 2.5 mg/day or more, including bone density and vertebral fracture assessment, and drug treatment for those at medium, high or very high risk [6].

Infection risk with corticosteroids

In a pooled analysis of 71 controlled trials, infectious complications occurred in 12.7% of 2,111 patients on systemic corticosteroids and 8.0% of 2,087 controls, a relative risk of 1.6 (95% CI 1.3 to 1.9) [4]. The rate was not increased below 10 mg of prednisone daily or 700 mg cumulatively [4]. The analysis did not involve testosterone cypionate.

Hematocrit and clot risk: testosterone's monitoring issue

Testosterone cypionate raises red cell mass. In a network meta-analysis of 29 placebo-controlled trials with 3,393 men, intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0% versus placebo (95% CI 2.9 to 5.1) [7]. A retrospective single-center review found erythrocytosis, defined as hematocrit above 50%, in 66.7% of men on injectable testosterone and 12.8% on gels; the injection group was younger and had higher baseline hematocrit, so this was not a randomized comparison [10].

The Depo-Testosterone label says to check hemoglobin and hematocrit periodically in long-term use [1]. It also lists venous thromboembolism and says to evaluate for deep vein thrombosis or pulmonary embolism and discontinue testosterone if a clot is suspected [1]. The label gives a periodic-check instruction, not a prednisone-specific hematocrit threshold [1].

Short prednisone courses are not risk-free

Prednisone risks start early. In a US claims study of 1,548,945 adults, within 30 days of starting a short oral corticosteroid course, the incidence rate ratios were 5.30 for sepsis (95% CI 3.80 to 7.41), 3.33 for venous thromboembolism (2.78 to 3.99) and 1.87 for fracture (1.69 to 2.07) [2]. The study was observational, and the risks fell over the next 31 to 90 days [2].